Examkin

Question

Difficulty: MediumHematology and Oncology

Connect the following antineoplastic agents with their most characteristic adverse effect that dictates specific clinical monitoring or preventive management.

  • TrastuzumabNon-dose-dependent, potentially reversible decline in left ventricular ejection fraction
  • BleomycinDose-dependent pulmonary toxicity leading to interstitial pneumonitis and fibrosis
  • CyclophosphamideAcrolein-mediated hemorrhagic cystitis, preventable with hydration and mesna
  • DoxorubicinCumulative, dose-dependent irreversible dilated cardiomyopathy

Answer

Trastuzumab pairs with non-dose-dependent reversible cardiomyopathy; Bleomycin pairs with pulmonary fibrosis; Cyclophosphamide pairs with acrolein-mediated hemorrhagic cystitis; Doxorubicin pairs with cumulative irreversible dilated cardiomyopathy.
Each antineoplastic agent has a well-defined toxicity profile that necessitates specific screening and prevention. Trastuzumab requires periodic echocardiograms to monitor for a reversible drop in left ventricular ejection fraction. Bleomycin requires baseline and follow-up pulmonary function testing due to the risk of interstitial lung disease. Cyclophosphamide requires aggressive intravenous hydration and co-administration of mesna to prevent acrolein-induced hemorrhagic cystitis. Doxorubicin requires strict tracking of the patient's lifetime cumulative dose to prevent irreversible, free radical-mediated dilated cardiomyopathy.

Step-by-Step Solution

1
Differentiate between the distinct cardiotoxic profiles of Trastuzumab and Doxorubicin.
Trastuzumab causes Type II cardiotoxicity (reversible, non-dose-dependent), while Doxorubicin causes Type I cardiotoxicity (irreversible, dose-dependent).
Both cause heart failure, but understanding the reversibility determines long-term monitoring and treatment cessation strategies.
2
Identify the classic pulmonary toxicity.
Bleomycin is matched with interstitial pneumonitis and pulmonary fibrosis.
Bleomycin clearance is reduced in the lungs, predisposing lung tissue to severe free radical damage and eventual fibrosis.
3
Identify the mechanism of urothelial toxicity.
Cyclophosphamide is matched with hemorrhagic cystitis.
Acrolein, a toxic metabolite of cyclophosphamide, accumulates in the bladder and must be actively neutralized with aggressive hydration and mesna.

Key Concept

Adverse effects of antineoplastic agents
Rate this question

Topics

Hematology and Oncology

More questions from this topic